4.7 Review

Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus

Publisher

ELSEVIER
DOI: 10.1016/j.bbadis.2021.166148

Keywords

Type 2 diabetes mellitus; Cardiovascular risk; Oxidative stress; Inflammation; Glycation; Novel biomarkers

Funding

  1. Eli Lilly
  2. MSD
  3. Novo Nordisk
  4. Novartis
  5. Sanofi-Aventis
  6. AstraZeneca
  7. Boehringer Ingelheim
  8. Coca-Cola
  9. Medtronic
  10. Merck
  11. Roche Diagnostics
  12. Sanofi
  13. TrigoCare International
  14. Pfizer
  15. Amgen
  16. Kowa
  17. Meda
  18. Mylan
  19. Merck Sharp Dohme
  20. Servier

Ask authors/readers for more resources

Diabetes is a major risk factor for cardiovascular disease, with high blood glucose leading to increased reactive oxygen species and affecting endothelial function and atherosclerotic plaque formation. Biomarkers play a crucial role in screening, prediction, diagnosis, and monitoring of cardiovascular risks associated with diabetes.
Diabetes represents the leading risk factor for the development of cardiovascular disease (CVD). Chronic hyperglycemia and/or acute post-prandial changes in blood glucose determine an increase in reactive oxygen species (ROS), which play a fundamental role in endothelial dysfunction and in the nuclear transport of proatherogenic transcription factors that activate the inflammasome. In addition, the glycemic alteration favors the formation and stabilization of atherosclerotic plaque through the mechanism of non-enzymatic glycation of different molecules, with the establishment of the so-called advanced glycosylation end products (AGE). Laboratory information provided by the level of biomarkers could make a quantitative and qualitative contribution to the clinical process of screening, prediction, prevention, diagnosis, prognosis and monitoring of cardiovascular (CV) risk linked to diabetes. This review describes the importance of specific biomarkers, with particular focus on novel ones, for stratifying and management of diabetes CV risk.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available